Does the media refer more to SRPT or EIKN?

In the previous week, Sarepta Therapeutics had 8 more articles in the media than Eikon Therapeutics. MarketBeat recorded 14 mentions for Sarepta Therapeutics and 6 mentions for Eikon Therapeutics. Sarepta Therapeutics' average media sentiment score of 1.07 beat Eikon Therapeutics' score of 0.91 indicating that Sarepta Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eikon Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, EIKN or PHVS?

Pharvaris is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eikon Therapeutics N/A N/A -$324.25M -$4.09 N/A Pharvaris N/A N/A -$198.79M -$3.05 N/A

Is EIKN or PHVS more profitable?

Eikon Therapeutics' return on equity of 0.00% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Eikon Therapeutics N/A N/A N/A Pharvaris N/A -61.40% -56.00%

Does the media favor EIKN or PHVS?

In the previous week, Pharvaris had 2 more articles in the media than Eikon Therapeutics. MarketBeat recorded 8 mentions for Pharvaris and 6 mentions for Eikon Therapeutics. Pharvaris' average media sentiment score of 1.58 beat Eikon Therapeutics' score of 0.91 indicating that Pharvaris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eikon Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharvaris 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is MESO or EIKN more profitable?

Company Net Margins Return on Equity Return on Assets Mesoblast N/A N/A N/A Eikon Therapeutics N/A N/A N/A

Does the media refer more to MESO or EIKN?

In the previous week, Eikon Therapeutics had 2 more articles in the media than Mesoblast. MarketBeat recorded 6 mentions for Eikon Therapeutics and 4 mentions for Mesoblast. Eikon Therapeutics' average media sentiment score of 0.91 beat Mesoblast's score of 0.29 indicating that Eikon Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eikon Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, EIKN or KLRA?

Eikon Therapeutics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eikon Therapeutics N/A N/A -$324.25M -$4.09 N/A Kailera Therapeutics N/A N/A -$148.96M -$3.65 thousand N/A

Is EIKN or KLRA more profitable?

Company Net Margins Return on Equity Return on Assets Eikon Therapeutics N/A N/A N/A Kailera Therapeutics N/A N/A N/A

Does the media refer more to EIKN or KLRA?

In the previous week, Eikon Therapeutics had 1 more articles in the media than Kailera Therapeutics. MarketBeat recorded 6 mentions for Eikon Therapeutics and 5 mentions for Kailera Therapeutics. Eikon Therapeutics' average media sentiment score of 0.91 beat Kailera Therapeutics' score of 0.36 indicating that Eikon Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eikon Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kailera Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is EIKN or PVLA more profitable?

Eikon Therapeutics' return on equity of 0.00% beat Palvella Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Eikon Therapeutics N/A N/A N/A Palvella Therapeutics N/A -47.84% -38.33%

Does the media favor EIKN or PVLA?

In the previous week, Palvella Therapeutics had 6 more articles in the media than Eikon Therapeutics. MarketBeat recorded 12 mentions for Palvella Therapeutics and 6 mentions for Eikon Therapeutics. Palvella Therapeutics' average media sentiment score of 1.11 beat Eikon Therapeutics' score of 0.91 indicating that Palvella Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eikon Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palvella Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Eikon Therapeutics (EIKN) Competitors

$10.96 -0.42 (-3.69%)

As of 09/3/2026 04:00 PM Eastern

Compare

EIKN vs. SRPT, PHVS, MESO, KLRA, and PVLA

Should you buy Eikon Therapeutics stock or one of its competitors? Eikon Therapeutics's main competitors and comparable companies include Sarepta Therapeutics (SRPT), Pharvaris (PHVS), Mesoblast (MESO), Kailera Therapeutics (KLRA), and Palvella Therapeutics (PVLA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Eikon Therapeutics compare to Sarepta Therapeutics?

Sarepta Therapeutics (NASDAQ:SRPT) and Eikon Therapeutics (NASDAQ:EIKN) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

In the previous week, Sarepta Therapeutics had 8 more articles in the media than Eikon Therapeutics. MarketBeat recorded 14 mentions for Sarepta Therapeutics and 6 mentions for Eikon Therapeutics. Sarepta Therapeutics' average media sentiment score of 1.07 beat Eikon Therapeutics' score of 0.91 indicating that Sarepta Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eikon Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eikon Therapeutics has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -13.48%. Eikon Therapeutics' return on equity of 0.00% beat Sarepta Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-13.48%	-1.60%	-0.66%
Eikon Therapeutics	N/A	N/A	N/A

86.7% of Sarepta Therapeutics shares are held by institutional investors. 6.9% of Sarepta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Eikon Therapeutics has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	1.10	-$713.41M	-$2.90	N/A
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A

Sarepta Therapeutics currently has a consensus price target of $25.06, indicating a potential upside of 9.00%. Eikon Therapeutics has a consensus price target of $25.00, indicating a potential upside of 128.10%. Given Eikon Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Eikon Therapeutics is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	5 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.20
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

Sarepta Therapeutics and Eikon Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Eikon Therapeutics compare to Pharvaris?

Eikon Therapeutics (NASDAQ:EIKN) and Pharvaris (NASDAQ:PHVS) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Eikon Therapeutics currently has a consensus price target of $25.00, indicating a potential upside of 128.10%. Pharvaris has a consensus price target of $51.08, indicating a potential upside of 43.23%. Given Eikon Therapeutics' higher probable upside, research analysts plainly believe Eikon Therapeutics is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Pharvaris had 2 more articles in the media than Eikon Therapeutics. MarketBeat recorded 8 mentions for Pharvaris and 6 mentions for Eikon Therapeutics. Pharvaris' average media sentiment score of 1.58 beat Eikon Therapeutics' score of 0.91 indicating that Pharvaris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eikon Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharvaris	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Pharvaris is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A

Eikon Therapeutics' return on equity of 0.00% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eikon Therapeutics	N/A	N/A	N/A
Pharvaris	N/A	-61.40%	-56.00%

Summary

Pharvaris beats Eikon Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Eikon Therapeutics compare to Mesoblast?

Mesoblast (NASDAQ:MESO) and Eikon Therapeutics (NASDAQ:EIKN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

Mesoblast has higher revenue and earnings than Eikon Therapeutics. Mesoblast is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$120.25M	18.51	-$57.50M	-$0.28	N/A
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A

In the previous week, Eikon Therapeutics had 2 more articles in the media than Mesoblast. MarketBeat recorded 6 mentions for Eikon Therapeutics and 4 mentions for Mesoblast. Eikon Therapeutics' average media sentiment score of 0.91 beat Mesoblast's score of 0.29 indicating that Eikon Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eikon Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

1.4% of Mesoblast shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Eikon Therapeutics	N/A	N/A	N/A

Mesoblast presently has a consensus target price of $39.00, suggesting a potential upside of 127.54%. Eikon Therapeutics has a consensus target price of $25.00, suggesting a potential upside of 128.10%. Given Eikon Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Eikon Therapeutics is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

Eikon Therapeutics beats Mesoblast on 6 of the 11 factors compared between the two stocks.

How does Eikon Therapeutics compare to Kailera Therapeutics?

Eikon Therapeutics (NASDAQ:EIKN) and Kailera Therapeutics (NASDAQ:KLRA) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

Eikon Therapeutics presently has a consensus price target of $25.00, suggesting a potential upside of 128.10%. Kailera Therapeutics has a consensus price target of $42.75, suggesting a potential upside of 171.60%. Given Kailera Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kailera Therapeutics is more favorable than Eikon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Eikon Therapeutics had 1 more articles in the media than Kailera Therapeutics. MarketBeat recorded 6 mentions for Eikon Therapeutics and 5 mentions for Kailera Therapeutics. Eikon Therapeutics' average media sentiment score of 0.91 beat Kailera Therapeutics' score of 0.36 indicating that Eikon Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eikon Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kailera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Eikon Therapeutics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A

Company	Net Margins	Return on Equity	Return on Assets
Eikon Therapeutics	N/A	N/A	N/A
Kailera Therapeutics	N/A	N/A	N/A

Summary

Kailera Therapeutics beats Eikon Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Eikon Therapeutics compare to Palvella Therapeutics?

Eikon Therapeutics (NASDAQ:EIKN) and Palvella Therapeutics (NASDAQ:PVLA) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

Eikon Therapeutics currently has a consensus target price of $25.00, suggesting a potential upside of 128.10%. Palvella Therapeutics has a consensus target price of $209.14, suggesting a potential upside of 34.52%. Given Eikon Therapeutics' higher probable upside, analysts clearly believe Eikon Therapeutics is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Palvella Therapeutics had 6 more articles in the media than Eikon Therapeutics. MarketBeat recorded 12 mentions for Palvella Therapeutics and 6 mentions for Eikon Therapeutics. Palvella Therapeutics' average media sentiment score of 1.11 beat Eikon Therapeutics' score of 0.91 indicating that Palvella Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eikon Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palvella Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eikon Therapeutics' return on equity of 0.00% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eikon Therapeutics	N/A	N/A	N/A
Palvella Therapeutics	N/A	-47.84%	-38.33%

40.1% of Palvella Therapeutics shares are owned by institutional investors. 17.2% of Palvella Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Palvella Therapeutics has higher revenue and earnings than Eikon Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A
Palvella Therapeutics	$42.81M	52.33	-$41.72M	-$4.83	N/A

Summary

Palvella Therapeutics beats Eikon Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Eikon Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EIKN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EIKN vs. The Competition

Export

Metric	Eikon Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$616.40M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-2.68	12.66	273.29	25.38
Price / Sales	N/A	1,309.08	613.45	97.56
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	1.27	16.29	12.89	6.14
Net Income	-$324.25M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-0.18%	0.34%	0.60%	-0.27%
1 Month Performance	14.64%	8.52%	5.73%	0.68%
1 Year Performance	N/A	52.66%	25.35%	14.84%

Eikon Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EIKN Eikon Therapeutics	3.6755 of 5 stars	$10.96 -3.7%	$25.00 +128.1%	N/A	$616.40M	N/A	N/A	384	News Coverage Positive News
SRPT Sarepta Therapeutics	2.4136 of 5 stars	$21.48 +2.1%	$25.06 +16.7%	+21.3%	$2.27B	$2.20B	N/A	1,372	Positive News
PHVS Pharvaris	3.9751 of 5 stars	$34.65 +0.1%	$51.08 +47.4%	+62.8%	$2.25B	N/A	N/A	30	Positive News Short Interest Increase
MESO Mesoblast	2.2677 of 5 stars	$16.68 -0.5%	$39.00 +133.9%	+33.1%	$2.17B	$120.25M	N/A	80
KLRA Kailera Therapeutics	2.5793 of 5 stars	$16.71 +8.5%	$42.75 +155.8%	N/A	$2.17B	N/A	N/A	145

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EIKN) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eikon Therapeutics (EIKN) Competitors

EIKN vs. SRPT, PHVS, MESO, KLRA, and PVLA

How does Eikon Therapeutics compare to Sarepta Therapeutics?

Summary

How does Eikon Therapeutics compare to Pharvaris?

Summary

How does Eikon Therapeutics compare to Mesoblast?

Summary

How does Eikon Therapeutics compare to Kailera Therapeutics?

Summary

How does Eikon Therapeutics compare to Palvella Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EIKN vs. The Competition

Eikon Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eikon Therapeutics (EIKN) Competitors

EIKN vs. SRPT, PHVS, MESO, KLRA, and PVLA

How does Eikon Therapeutics compare to Sarepta Therapeutics?

Does the media refer more to SRPT or EIKN?

Is SRPT or EIKN more profitable?

Do institutionals and insiders believe in SRPT or EIKN?

Which has higher earnings and valuation, SRPT or EIKN?

Do analysts prefer SRPT or EIKN?

Summary

How does Eikon Therapeutics compare to Pharvaris?

Do analysts prefer EIKN or PHVS?

Does the media favor EIKN or PHVS?

Which has higher valuation and earnings, EIKN or PHVS?

Is EIKN or PHVS more profitable?

Summary

How does Eikon Therapeutics compare to Mesoblast?

Which has stronger valuation & earnings, MESO or EIKN?

Does the media refer more to MESO or EIKN?

Do institutionals and insiders hold more shares of MESO or EIKN?

Is MESO or EIKN more profitable?

Do analysts rate MESO or EIKN?

Summary

How does Eikon Therapeutics compare to Kailera Therapeutics?

Do analysts prefer EIKN or KLRA?

Does the media refer more to EIKN or KLRA?

Which has higher earnings & valuation, EIKN or KLRA?

Is EIKN or KLRA more profitable?

Summary

How does Eikon Therapeutics compare to Palvella Therapeutics?

Do analysts prefer EIKN or PVLA?

Does the media favor EIKN or PVLA?

Is EIKN or PVLA more profitable?

Do insiders & institutionals hold more shares of EIKN or PVLA?

Which has stronger earnings and valuation, EIKN or PVLA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EIKN vs. The Competition

Eikon Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools